Meeting Modern Data Integrity and Compliance Requirements
White Paper Sep 01, 2017
The FDA was perhaps understating a point when it said in its April 2016 Draft Guidance: Data Integrity and Compliance with cGMP1 that the increasing number of data integrity-related cGMP violations identified during its inspections was ‘troubling’. In fact, 21 out of 28 warning letters issued by the agency between January 2015 and May 2016 involved data integrity issues in drug manufacturing.
Ultimately, whether you are a drug manufacturer, clinical research organisation (CRO) or pharmaceutical R&D company, the accuracy and completeness of data is critical for safe product development, and any breach of data integrity could have serious implications for human health.
Download this whitepaper to learn more about meeting modern data integrity and compliance requirements.
Learn more about modern data integrity and compliance requirements in this free to attend webinar.
Related White Papers
Exploring the Hallmarks of Cancer with Real-time Live-cell AnalysisWhite Paper
The constantly evolving picture of tumor biology is helping to shed new light on the behavior of many cancers, as well as providing new pharmacological targets and treatment strategies.READ MORE
Fully Automated Sensitive Determination of Immunosuppressant Drugs in Whole Blood, using High Quality Internal StandardizationWhite Paper
Measurement of immunosuppressant drugs is essential during organ transplantation. Under-dosing can lead to organ rejection, while over-dosing can cause serious toxicity.READ MORE
8 Reasons why it’s Time to Upgrade to Automated ImagingWhite Paper
Why automated image analysis is rapidly replacing manual microscopy for characterizing particle shape and how combining it with Raman spectroscopy adds chemical identification.READ MORE